HK$5.68
3.57%
Hong Kong, Sep 22, 03:17 pm HKT. Market open.
ISIN
CNE100006T44
Symbol
2565

Pegbio Co-h Stock price

HK$5.89
+0.01 0.17% 1M
-53.12 90.03% 6M
-63.12 91.47% YTD
-45.57 88.56% 1Y
-5.68 49.09% 3Y
-5.68 49.09% 5Y
-5.68 49.09% 10Y
-5.68 49.09% 20Y
Hong Kong, Closing price Mon, Sep 21 2026
+0.09 1.55%
ISIN
CNE100006T44
Symbol
2565
Industry

Is Pegbio Co-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$2.3b
Enterprise Value
HK$2.0b
Net debt
positive
Cash
HK$478.8m
Shares outstanding
391.1m
Valuation (TTM | estimate)
P/E
-
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
7.3
Financial Health
Equity Ratio
74.8%
Return on Equity
-46.5%
ROCE
-
ROIC
-
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
-
Employees
58
Rev per Employee
HK$0.0

Pegbio Co-h Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Pegbio Co-h forecast:

2x Hold
22%
7x Sell
78%

Analyst Opinions

9 Analysts have issued a Pegbio Co-h forecast:

Hold
22%
Sell
78%

Financial data from Pegbio Co-h

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 109 109
41% 41%
-
- Research and Development Expense 129 129
318% 318%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -238 -238
117% 117%
-
Net Profit -253 -253
131% 131%
-

In millions HKD.

Don't miss a Thing! We will send you all news about Pegbio Co-h directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. The firm's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The firm's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The firm's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).

Head office China
Employees 58
Website www.pegbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today